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Abstract
Background: The antihypertensive compound hydralazine is a known demethylating agent. This phase I study
evaluated the tolerability and its effects upon DNA methylation and gene reactivation in patients with untreated
cervical cancer.
Methods: Hydralazine was administered to cohorts of 4 patients at the following dose levels: I) 50 mg/day, II) 75
mg/day, III) 100 mg/day and IV) 150 mg/day. Tumor biopsies and peripheral blood samples were taken the day
before and after treatment. The genes APC, MGMT; ER, GSTP1, DAPK, RARβ , FHIT and p16 were evaluated pre
and post-treatment for DNA promoter methylation and gene expression by MSP (Methylation-Specific PCR) and
RT-PCR respectively in each of the tumor samples. Methylation of the imprinted H19 gene and the "normally
methylated" sequence clone 1.2 was also analyzed. Global DNA methylation was analyzed by capillary
electrophoresis and cytosine extension assay. Toxicity was evaluated using the NCI Common Toxicity Criteria.
Results: Hydralazine was well tolerated. Toxicities were mild being the most common nausea, dizziness, fatigue,
headache and palpitations. Overall, 70% of the pretreatment samples and all the patients had at least one
methylated gene. Rates of demethylation at the different dose levels were as follows: 50 mg/day, 40%; 75 mg/day,
52%, 100 mg/day, 43%, and 150 mg/day, 32%. Gene expression analysis showed only 12 informative cases, of these
9 (75%) re-expressed the gene. There was neither change in the methylation status of H19 and clone 1.2 nor
changes in global DNA methylation.
Conclusion: Hydralazine at doses between 50 and 150 mg/day is well tolerated and effective to demethylate and
reactivate the expression of tumor suppressor genes without affecting global DNA methylation
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Background
Cancer is considered to be a disease of the genome that
results from a plethora of genetic and epigenetic lesions.
Among the epigenetic alterations, DNA hypermethylation
is thought to play an important role in tumor develop-
ment and progression [1]. In this regard, at least three
functional DNA methyltransferases (DNMTs) have been
identified, the most abundant is DNMT1 which preferen-
tially methylates hemi-methylated DNA [2], and plays a
key role in imprinting and X-chromosome inactivation
during embryogenesis [3,4]. DNTM1 localizes to replica-
tion foci [5], at least in part by interacting with proliferat-
ing cell nuclear antigen (PCNA), a protein closely
involved in DNA replication. It is therefore responsible for
maintaining proper methylation levels during replication
and possibly repair [6]. Other known functional methyl-
transferases are DNMT3a and DNMT3b, which are
responsible for de novo methylation during embryogene-
sis [7]. DNMT3a and DNMT3b have equal preferences for
hemi-methylated and non-methylated DNA, and so have
been classified as de novo methyltransferases [8]. DNA
methylation can directly interfere with transcriptional fac-
tor binding and thus inhibit replication [9], with methyl-
CpG binding proteins which bind methylated DNA and
with regulatory proteins that inhibit transcription [10]. In
addition, both DNMT1 and methyl-binding proteins
(MBP), such as methyl-CpG-binding protein 2 (MeCP2)
recruit histone deacetylases which deacetilate histone core
tails leading to tighter chromatin packaging, reducing the
access of transcriptional factors to DNA [11,12].
Cancer cells are considered to have global hypomethyla-
tion and regional hypermethylation. Hypermethylated
regions are CpG islands, CpG and GpC rich sequences 1
kb long found proximal to gene promoters involved in
transcriptional control [13]. These islands are associated
with roughly half of all genes [15], their methylation can
repress transcription in a manner analogous to a mutation
or deletion (16). It is thought that tumor suppressor gene
promoter hypermethylation contributes to their transcrip-
tional silencing [14]. Furthermore, there is a growing list
of tumor suppressor genes in both sporadic and familial
cancers which are found to be transcriptionally silenced
by hypermethylation [17].
In this regard, tumor suppressor gene transcriptional reac-
tivation through promoter de-methylation represents an
attractive strategy for anticancer treatment. Substantial
preclinical studies characterizing DNA methylation inhib-
itors have shown cancer cell line growth arrest in vitro and
antitumor effects in animal models, including survival
prolongation [18-20]. These concepts are supported by
the transforming effect of exogenous DNA methyltrans-
ferase gene expression observed in fibroblasts [21] as well
as by the malignant phenotype reversion documented
using antisense oligonucleotides against this gene [22].
These findings have paved the way for the clinical testing
of demethylating agents in cancer.
Nucleoside deoxycytidine analogs formerly known as
classic cytotoxic agents and later known as DNA methyla-
tion inhibitors show poor activity against solid tumors
[23] however, 5-aza-2'-deoxycytidine has recently gained
considerable attention and is presently being tested as a
demethylating agent for the treatment of hematological
neoplasms [24]. MG98, is an antisense oligodeoxynucle-
otide directed against the 3' untranslated region of the
DNA methyltransferase-1 enzyme mRNA that has been
tested in clinic [23]. A phase I study using biweekly
administration of this agent, showed no consistent
decrease of mRNA levels in the peripheral blood cells of
patient [25]. Although this agent has shown activity in
xenografts models of nude mice, demonstration of antitu-
mor efficacy in humans is pending.
Our group has recently shown in vitro and in vivo pro-
moter demethylation and tumor suppressor gene tran-
scriptional reactivation mediated by the antihypertensive
compound hydralazine [26]. Its DNA demethylating
activity can be explained by the interaction between its
Nitrogen atoms with residues Lys162 and Arg240 of the
DNA methyltransferase active site as showed in a silico
model [27]. Hydralazine is a well-tolerated drug devoid of
the common side effects of cytotoxic chemotherapy
agents, however, its hypotensive effects could limit its use
in a clinical setting, we thus felt desirable to determine the
dose at which its demethylating activities were observed




Previously untreated patients with histological diagnosis
of carcinoma of the cervix were entered into this phase I
study. The following inclusion criteria were applied: 1)
age between 18 and 75 years; 2) Karnofsky status 70% or
higher; 3) hematological, renal and hepatic functions as
follows: hematological: Hemoglobin equal or higher than
10 g/L, leukocytes >4000/mm3, platelets >100 000/mm3,
total bilirubin and transaminases <1.5× the normal upper
limit, and normal serum creatinine; 4) a normal chest X-
ray and 5) signed informed consent. Exclusion criteria
were: 1) history of allergy to hydralazine; 2) any past or
current cardiovascular condition (higher blood pressure,
heart failure, etc., that required pharmacological treat-
ment; 3) any past or current rheumatic or autoimmune
disease; 4) uncontrolled infection or other systemic dis-
eases; 5) concomitant treatment with any experimental
drug; 6) pregnant or nursing women; 7) mental illness;
and 8) previous or concomitant malignant diseases otherBMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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than non-melanoma skin cancer. The Institutional Regu-
latory Board approved the study protocol.
Clinical samples and nucleic acids extraction
Biopsies were taken from areas with visible macroscopic
cervical tumor using a sterile biopsy punch the day before
and the day after the 10 days of hydralazine treatment.
The specimen was immediately frozen at -20°C for further
processing. In addition, a blood sample of 10 mL was
drawn from the arm by venipuncture for subsequent
mononuclear cell DNA extraction. In addition, the surgi-
cal specimen of an early stage cervical cancer patient
undergoing radical hysterectomy was multi-sampled in
the surgical room by taking 4 small fragments of the mac-
roscopic tumor from separate areas. Genomic DNA was
isolated from the tumor tissues and from the buffy coat
layer of blood samples using the standard method of pro-
teinase K digestion and phenol-chloroform extraction.
RNA from tumor biopsies was obtained using the TriRea-
gent (Gibco BRL Grand Island, New York) RNA extraction
kit following the manufacturer instructions.
Hydralazine treatment
Twenty four hours after tumor and blood sampling
patients where divided into the following groups and
started on oral hydralazine for a ten day period: I) 25 mg
every 12 hours, II) 25 mg every 8 hours; III) 50 mg every
12 hours; and IV) 50 mg every 8 hours. Toxicity was
assessed at the end of study period (10 days), with special
emphasis on the presence, throughout the treatment days,
of known signs and symptoms associated with hydrala-
zine treatment (hypotension, tachycardia, palpitations,
syncope, sweating, headache, dizziness and fluid reten-
tion). The study period ended at day ten and patients went
to receive definitive treatment.
Analysis of DNA methylation in the tumor
The methylation status of genes was determined in the
biopsies pre and post-treatment. The gene set studied was:
p16, RARβ , MGMT, ER, FHIT, APC, DAPK and GSTp1
which were analyzed by methylation-specific PCR as pre-
viously described [28]. In addition, the four fragments of
the tumor of the untreated patient were analyzed for
methylation of the DAPK gene. Briefly, 1 µg of DNA in a
volume of 100 µl of each sample was denaturated with
freshly prepared NaOH at a final concentration of 0.2 M,
and modified according to the manufacturer instructions
of the DNA Modification kit (Intergen, Purchase, New
York). The PCR mixture contained 2 µl of 10X PCR buffer,
0.5 U of Taq Gold polymerase, dNTPs (each 1.25 mM),
300 ng of primers and bisulfite-modified DNA in a final
volume 20 µl. Products were visualized in a 2% agarose
gel under UV light. The primers and conditions for PCR
are shown in Table 1. A gene was deemed methylated
whenever a band was present after amplification with the
methylated, or both methylated and unmethylated set of
primers. On the contrary, a gene was deemed unmethyl-
ated when a band was present after amplification with the
unmethylated set in the absense of band with the methyl-
ated set. An exception to these criteria was when in the
pretreatment biopsy there was only a methylated band
but both unmethylated and methylated bands after
Table 1: Primers and conditions used for MSP.
Primer set Sense 5'-- 3' Antisense 5'--- 3' Size Annealing
p16 M TTATTAGAGGGTGGGGCGGATCGC GACCCCGAACCGCGACCGTAA 150 62°C
p16 U TTATTAGAGGGTGGGGTGGATTGT CAACCCCAAACCACAACCATAA 151 62°C
RARβ M TCGAGAACGCGAGCGATTCG GACCAATCCAACCGAAACGA 146 55.5°C
RARβ U TTGAGAATGTGAGTGATTTGA AACCAATCCAACCAAAACAA 146 55.5°C
MGMT M TTTCGACGTTCGTAGGTTTTCGC AACCAATCCAACCAAAACAA 81 55.7°C
MGMT U TTTGTGTTTTGATGTTTGTAGGTTT AACTCCACACTCTTCCAAAAAC 93 55.7°C
FHIT M TTGGGGCGCGGGTTTGGGTTTTTA CGTAAACGACGCCGACCCCACTA 74 55.5°C
FHIT U TTGGGGTGTGGGTTTGGGTTTTTA CATAAACAACACCAACCCCACTA 74 55.5°C
DAPK M GGATAGTCGGATCGAGTTAACGT CCCTCCCAAACGCCGA 98 55.7°C
DAPK U GGAGGATAGTTGGATTGAGTTAAT CAAATCCCTCCCAAACACCAA 106 55.7°C
APC M TATTGCGGAGTGCGGGTC TCGACGAACTCCCGACGA 100 56°C
APC U GTGTTTTATTGTGGAGTGTGGGTT CCAATCAACAAACTCCCAACAA 110 56°C
GSTp1 M TTCGGGGTGTAGCGGTGGTC GCCCCAATACTAAATCACGACG 91 56°C
GSTp1 U GATGTTTGGGGTGTAGTGGTTGTT CCACCCCAATACTAAATCACAACA 97 56°C
H19 M TTATAAAATCGAAAATTACGCGCGA AGATGATTTTCGTGAATTTTGCG 136 55°C
H19 U TATAATTATAAAATCAAAAATTACA TTTTAGATGATTTTTGTGAATTTT 145 55°C
ER M CGGTTGGAGTTTTTGAATCGTTC CTAGCGTTAACGACGACCG 151 55°C
ER U ATGAGTTGGAGTTTTTGAATTGTTT ATAAACCTACACATTAACAACAACCA 158 55°C
Clone 1.2 M ATGAGTTGGAGTTTTTGAATTGTTT AATAATAAACGTAACGCCCGCGAAC 258 63°C
Clone 1.2 U GGTTGTTTGGTTTTTATTGGGATGTTTTT CCTAAATAATAAACATAACACCCACAAAC 258 63°CBMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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treatment.
Analysis of DNA methylation in mononuclear cells of 
peripheral blood
The methylation status of the imprinted H19 gene as well
as the clone 1.2 which is known to be normally methyl-
ated and not subjected to imprinting [29] was also ana-
lyzed by methylation specific PCR. The positive control
for unmethylation in the clone 1.2 sequence was DNA
from cultured cells treated with ethionine. Primers and
conditions are shown in Table 1.
Analysis of gene expression
Total RNA obtained from pre and post-treatment biopsies
was reverse transcribed using a RT-PCR kit (Perkin Elmer;
Branchburg, New Jersey) following the manufacturer
instructions. Primers and conditions for amplifications
are shown in Table 2.
Quantification genomic 5-methylcytosine DNA content by 
capillary electrophoresis
Adenine, thymine, guanine, uracyl, cytosine and 5-
methyl-cytosine were purchased from Sigma (St. Louis,
MO; USA). Bases were dissolved at 2.4 mM in 0.1 M HCL,
0.01 M HCL, or Milli-Q-grade water (Millipore, Bedford,
MA) and filtered through 0.45 µm pore size filters (Milli-
pore). Briefly, extracted DNA samples were resuspended
in TE buffer at (1 µg/µl). Hydrolysis of DNA was carried
out by incubating 40 µg of DNA in 2 mL 88% v/v formic
acid at 140°C into a sealed ampoule for 90 min. After
hydrolysis, samples were reduced to dryness by speedvac
concentration and redissolved in 30 µL of Milli-Q-grade
water. DNA samples of pre and post-treatment biopsies
were analyzed for 5-methylcytosine content by capillary
electrophoresis (CE) as reported by us [30]. For the CE
procedure, an uncoated fused-silica capillary (Beckman-
Coulter; 60 cm × 75 µm; effective length, 44.5 cm) was
used in a CE system (P/ACE MDQ; Beckman-Coulter)
connected to a data-processing station (32 Karat soft-
ware). The running buffer was 20 mM NaCO3 (pH 9.6 ±
1) containing 80 mM SDS. Running conditions were
25°C with an operating voltage of 20 kV. On-column
absorbance was monitored at 223 nm. Before each run,
the capillary system was conditioned by washing with the
running buffer for 2 min. Buffers and washing solutions
were prepared with Milli-Q water and filtered throughout
0.45-µm filters. Hydrolyzed samples, previously filtered
through 0.45 µm pore filters, were injected under pressure
(0.5 p.s.i.) for 15s. The relative methylation of each DNA
sample was taken as the percentage of mC in total cytosine:
mC peak area × 100/(C peak area + mC peak area).
Methylation pattern in global DNA
Global DNA methylation was evaluated by the cytosine-
extension assay [31] which is based on the use of methyl-
ation-sensitive restriction endonuclease that leave a 5'
guanine overhang after DNA cleavage, with subsequent
single nucleotide extension with radiolabeled
[(3)H]dCTP. Briefly 1 µg of DNA from tumor tissue was
digested overnight with BssHII according to the manufac-
turer. Single nucleotide extension reaction was performed
in a 25 µl reaction mixture containing 0.25 µg of DNA, 1X
buffer II, 1 mM MgCl, 0.25 U of DNA polymerase (Perkin
Elmer; Branchburg, New Jersey [3H]dCTP (Ci/mmol) and
incubated at 56°C for 1 hour, then placed on ice. The reac-
tion mixture was then applied to sephadex G25 column.
For the column chromatography, each sephadex G25 col-
umn was centrifuged for 10 sec., at 5000 rpm to remove
the buffer and loaded with the reaction mixture. After
loading the samples to the column, the radiolabeled DNA
was collected by centrifugation of the column and mixed
with liquid scintillation for the determination of radioac-
tivity. Results were expressed as the percentage change
from the average controls which were tumor samples of
patients pre and post-treatment without BssHII digestion.
Results
Study group
A total of 16 patients were studied. All of them were chem-
otherapy or radiation naive and had a macroscopic tumor
accessible for punch biopsy. Their mean age was 51.8
(35–75 years), all cases were squamous histology and
Table 2: Primers and conditions used for RT-PCR
Primer set Sense 5'-- 3' Antisense 5'--- 3' Size Annealing
p16 AGCCTTCGGCTGACTGGCTGG CTGCCCATCATCATGACCTGG 150 60°C
RARβ GACTGTATGGATGTTCTGTCAG ATTTGTCCTGGCAGACGAAGCA 146 50°C
MGMT GCTGCAGACCAVCTCTGTGGCACG GCCGCCTCTTCACCATCCCG 81 50°C
FHIT ATGTCGTTCAGATTTGGCCAAC TCATAGATGCTGTCATTCCTGT 340 53°C
DAPK AACCCATCATCCATGCCATC TCTCTCCTTCTCGGTTCTTGA 200 51°C
APC GAGACAGAATGGAGGTGCTGC GTAAGATGATTGGAATTATCTTCT 180 56°C
GSTp1 TCCGCTGCAAATACATCTCC TGTTTCCCGTTGCCATTGAT 320 50°C
ER GGAGACATGAGAGCTGCCAAC CCAGCAGCATGTCGAAGATC 480 55°CBMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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staged as FIGO stage IIB and IIIB. The status performance
was 0–1 in all patients (Table 3).
Treatment compliance and side effects
All patients completed the prescribed medication and
reported that hydralazine treatment was well tolerated.
Side effects as evaluated by the Common Toxicity Criteria
are showed in Table 4. Grade 1 fatigue, headache and pal-
pitations were observed in 50% of patients; grade 1 nau-
sea was present in 37% of cases, being grade 2 in only one
patient. Only 2 out of 16 patients presented dizziness
grades 1 and 2 respectively. No patient stopped treatment
due to adverse effects. We observed no side-effect dose
relationship.
Gene promoter methylation
Methylation analysis of the biopsies taken before and
after 10 days of hydralazine administration was per-
formed in all 16 patients. Methylation results involving
the genes analyzed were variable. Overall, 70% (89 out of
128) of the pretreatment samples analyzed (8 genes for
each of the 16 pre-treatment biopsies) had at least one
methylated gene, and all 16 patients had at least one
methylated gene. Analysis by individual genes showed the
following rates of methylated genes: APC (94%), ER
(25%) FHIT (88%), GSTp1 (88%), MGMT(81%),
p16(19%), RARβ  (62%), and DAPK (100%), irrespective
of the dose of hydralazine used, the post-treatment biop-
sies showed a variable demethylation rate according to the
gene, varying from 15% (2/13 samples) for the MGMT
gene, to 67% of demethylation for the p16 gene (2 out of
3 samples), (Figure 1A). Representative cases of the results
are shown in Figure 1B. Correlation between demethyla-
tion analysis and dose level revealed the following results:
at 50 mg a day, 40% of methylated genes suffered demeth-
ylation; at 75 mg it was 52%, at 100 mg dose the rate was
43%, and 32% for the 150 mg dose (Figure 1C).
Gene expression
All cases showed expression of β  actin. Gene expression
analysis showed that 90% (116 out of 128) of the tumor
samples expressed the messenger in the pre-treatment and
post-treatment biopsies regardless of methylation status,
hence were not informative. On the other hand, there
were only 12 informative cases. Of these 12 cases, three
(25%) (having only the methylated band pretreatment)
showed no re-expression after treatment (2/ DAPK, 1/
GSTp1 cases). These three cases received the 50 mg dose.
In the remaining 9 cases (75%) expression of the gene was
re-induced after treatment. These nine cases behaved as
follows: Five cases were RT-PCR negative pretreatment
(only methylated band) and converted positive post-treat-
ment, displaying methylated and unmethylated bands
(FHIT two cases -100 and 150 mg doses- MGMT two cases
-75 and 150 mg doses, GSTp1 one case -50 mg dose).
Three cases RT-PCR negative pre-treatment with methyl-
ated band which converted to unmethylated and expres-
sion positive in the post-therapy biopsy (DAPK and ER
genes at 75 mg, GSTp1 at 150 mg dose), and finally, a RT-
PCR negative in the pre-treatment biopsy despite having
methylated and unmethylated bands which converted to
RT-PCR positive accompanied by only unmethylated
band (GSTp1 case at 75 mg). Table 5, Figure 2D. Three
representative cases are shown in Figure 2A, B, C.
Methylation heterogeneity in tumor samples
Because the sampling of tumor may lead to tissue speci-
mens with different degree of "contamination" with non-
malignant that may affect the result of methylation in the
post-treatment, biopsies, all samples were analyzed by a
pathologist. The results showed that in all biopsy samples
the content of malignant cells varied from 30 to 70%. A
representative set is shown in Figure 3A. In addition, we
reasoned that if tumor heterogeneity were of a magnitude
to yield different methylation patterns in the tumors
regardless of the treatment, then multisampling a tumor
Table 3: Clinical characteristics of patients
Number 16








16  ( 3 8 % )
*International Federation of Gynecology and Obstetrics,
** World Health Organization Criteria
Table 4: Toxicity to hydralazine expressed by number of patients 
suffering the event (16 patients)
Toxicity 4 Patients in each dose level (mg
50 75 100 150
Nausea 2/4 - 2/4* 2/2
V o m i t i n g ----
Dizziness - 1/4* 1/4 -
Fatigue 2/4 2/4 3/4 1/4
Flushes - - - -
Headache 2/4 1/4 3/4 2/4
Edema - - - -
Palpitations 1/4 2/4 2/4 3/4
* Grade 2 toxicity. All other were grade 1.BMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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1A. Pre- (dark bars) and post-hydralazine treatment (light bars) Figure 1
1A. Pre- (dark bars) and post-hydralazine treatment (light bars). The bars represent the number of patients that showed meth-
ylation for each studied gene from each of the 16 patients. 1B. Representative cases of genes (M methylated, U unmethylated; 
pre/post): M/M; M/U; U/U, M/U; MU/U; M/ U-M. 1C. Percentage of demethylation after treatment according to the dose. Per-
centage was calculated considering 100% methylation the total number of pre-treatment methylated genes in each cohort of 4 
patientsBMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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with subsequent methylation analysis of each of the
tumor fragments will render zones with different methyl-
ation pattern. The analysis of the surgical specimen of an
untreated patient showed that the methylation of the
DAPK gene promoter was the same in the four fragments
of the tumor. Figure 3B.
Methylation of imprinted and "normally methylated" 
genes
The methylation status of the imprinted gene H19 was
investigated in the DNA extracted from peripheral blood
cells. As shown in Figure 4, no change in the expected pat-
tern of bands was observed after treatment, all patients
showed bands with the methylated and unmethylated set
of primers. A consistent pattern of methylation also was
observed in all patients analyzed for the "normally
methylated" sequence clone 1.2. No case showed demeth-
ylation at this locus.
Global methylation
Global tumor DNA methylation was evaluated by two
methods, capillary electrophoresis and cytosine exten-
sion. Enough DNA to perform capillary electrophoresis
was only available in five cases (four patients taking 100
mg, and one taking 150 mg/day respectively). The relative
methylation of each DNA sample was taken as the per-
centage of dmC in total cytosine. Figure 5A shows the rel-
ative methylation in theses cases. Remarkably, relative
methylation in all cases was between 34.2 and 38.4% and
there was no change in methylation levels after hydrala-
zine treatment (37.3% ± 0.81 and 36.3% ± 1.1 pre and
post-treatment respectively). An electropherogram show-
ing the separation of the analytes of interest, C and mC
peak are shown in Figure 5B. In the cytosine extension
assay, the extent of [(3)H]dCTP incorporation after
restriction enzyme treatment is directly proportional to
the number of unmethylated (cleaved) CpG sites. The
results of this assay showed no statistically significant
changes in the tumor samples pre and post-treatment as
the percentage increase in radiolabel incorporation were
15% ± 31.3% and 7% ±16.7% respectively, Figure 5C.
Discussion
Malignant tumors frequently silence genes that control
cell growth, differentiation and apoptosis through DNA
methylation at their promoter regions; consequently,
their reactivation by DNA methylation inhibitors has
raised considerable interest as anti-tumor therapy. The
present focus on DNA methylation has opened a new way
to clinically test the ability of diverse compounds as
tumor suppressor gene transcriptional reactivators. We
previously reported that hydralazine induces in vitro and
in vivo, demethylation and transcriptional reactivation at
the mRNA and protein levels of the ER, RARβ  and p16
genes [26]. The present study confirms our previous find-
ings in a larger number of patients receiving different
hydralazine dosage levels for a 10 day period. Our results
demonstrate that hydralazine can demethylate and re-
express tumor suppressor genes in previously untreated
cervical cancer patients in all the tested dosages. Theses
effects are accompanied by no change in global tumor
DNA methylation evaluated by two methods, and lack of
demethylation in the imprinted gene H19 and the
"normally methylated" 1.2 clone in peripheral mononu-
clear blood cells.
Hydralazine, a widely available peripheral vasodilator
agent, has been extensively used for high blood pressure,
heart failure and pregnancy-associated hypertensive disor-
ders [32-34]. Hence, its evaluation as a demethylating
Table 5: Methylation and gene re-expression of the 12 informative cases.
Pre-treat Post-treat Re-expression
G e n e d o s e  l e v e l MUMU Y e s / N o
D A P K 5 0 +-+- N o
D A P K 5 0 +-+- N o
GSTp1 50 + - + - No
FHIT 100 + - + + Yes
FHIT 150 + - + + Yes
MGMT 75 + - + + Yes
MGMT 150 + - + + Yes
GSTp1 50 + - + + Yes
DAPK 75 + - - + Yes
ER 75 + - - + Yes
GSTp1 150 + - - + Yes
GSTp1 75 + + - + YesBMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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agent in a clinical trial involving cancer patients could
proceed with no major concerns regarding unexpected
toxicity and long-term side effects aside of its known
capacity to induce a lupus-like condition [35]. Evaluation
of tumor DNA demethylating agents in patients bearing
solid tumors is troublesome due to the need of repeated
tumor sampling. Cervical cancer is easily accessible for
Representative cases correlating methylation and re-expres- sion before and after hydralazine treatment Figure 2
Representative cases correlating methylation and re-expres-
sion before and after hydralazine treatment. 2A is a patient 
treated with 75 mg/day that demethylated and re-expressed 
the DAPK gene. 2B corresponds to a patient receiving 150 
mg/day who showed only the methylated band pre-treat-
ment, but both bands after treatment, which correlated with 
re-expression of MGMT. 2C is a 50 mg/day patient which 
failed to demethylate the DAPK gene and therefore lacked 
expression. 2D represents the distribution of informative 
cases. From the 128 genes/cases, 116 were RT-PCR positive 
regardless of the methylation status, hence were not inform-
ative. In the remaining 12 cases, nine demethylated and re-
expressed the gene.
3A. Photomicrography of a representative set of pre and  post-treatment tumor biopsies showing that the malignant  component represents almost the half of the tumor Figure 3
3A. Photomicrography of a representative set of pre and 
post-treatment tumor biopsies showing that the malignant 
component represents almost the half of the tumor. 3B. 
Methylation analysis of the DAPK gene in the four fragments 
of the tumor biopsy of an untreated cervical cancer patient. 
Despite all fragments contained different proportions of 
malignant cells and stroma the four samples show methylated 
and unmethylated bands.
DNA methylation analysis obtained from peripheral mono- nuclear cells of genes "imprinted or normally methylated" Figure 4
DNA methylation analysis obtained from peripheral mono-
nuclear cells of genes "imprinted or normally methylated". 
Clone 1.2 remained methylated in all cases whereas for the 
imprinted H19 gene, the pattern of U and M alleles did not 
change.BMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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repeated tumor sampling and thus we chose to study
patients with newly diagnosed cervical cancer. In order to
avoid treatment delay in the studied group, we scheduled
the present study between the date of diagnosis and the
beginning of chemoradiation. In addition, three recent
publications have consistently shown a number of tumor
suppressor genes to be methylated in primary cervical
tumors [36-38]. Our results demonstrate that 70% of the
pretreatment samples analyzed had at least one gene
methylated, and all 16 patients had at least one methyl-
ated gene. The methylation frequency ranged from 3/16
(19%) to 16/16 (100%) for p16 and DAPK genes respec-
tively. (Figure 1A). Despite the fact that our global gene
methylation frequency is remarkably similar to the fre-
quencies reported by other authors [36-38] who found
86%, 74% and 79% respectively, we encountered differ-
ences in individual gene methylation frequencies which
most likely stem from the different patient populations
analyzed such as invasive versus pre-invasive disease,
tumor histologies, and clinical stages (Table 6). Neverthe-
less, our results and those obtained in other studies as
shown in Table 6, suggest that cervical cancer is a good
tumor model to evaluate the effect of DNA demethylating
agents upon a small number of individual genes found
consistently methylated in high proportion. As expected,
there were genes "fully" unmethylated or "fully" methyl-
ated but we also observed cases showing both methylated
and unmethylated bands. Such ambiguous methylation
pattern as evaluated by methylation-specific PCR is com-
monly observed when patient tumor samples are studied
which probably results from certain degree of normal tis-
sue/cell biopsy contamination. This may rise concerns on
whether the demethylating effect showed post-treatment
is consequence of the treatment and not due tumor heter-
ogeneity, however, in all pretreatment and post-treatment
biopsies the major component of the tumor was malig-
nant cells (Figure 3A); On the other hand, if demethyla-
tion were the result of chance alone we would expect to
have cases in both directions, that is, methylated tumors
that demethylated, and demethylated tumors that methyl-
ated. The latter never occurred, which strongly supports
that the demethylating effect was caused by hydralazine.
To gain further insight into the issue of tumor heterogene-
ity, we multi-sampled a tumor and submitted to methyla-
tion analysis each of the tumor fragments containing
malignant cells. As shown in Figure 3B, there were no
changes in the pattern of methylation in the four separate
tumor areas of the tumor. This result strongly supports the
observation that demethylation is an effect of
hydralazine.
Hydralazine is considered a safe drug with hypertension
and hearth failure dosing ranging from 50 mg day to 400
mg/day [33,34]. However, higher doses produce
symptomatic side effects mainly derived from its
cardiovascular effects. Based on this, we felt important to
determine the lowest possible dose that induced DNA
demethylation to be used in future clinical trials. In the
present study we demonstrate that at a dose range
between 50 mg and 150 mg a day for 10 days, hydralazine
5A. Capillary electrophoretic analysis of global methylation.  Relative methylation showed no variation in percentage of  mC after treatment (37.3% versus 36.3%) Figure 5
5A. Capillary electrophoretic analysis of global methylation. 
Relative methylation showed no variation in percentage of 
mC after treatment (37.3% versus 36.3%). 5B is a electrophe-
rogram showing the separation of C and mC. 5C is the per-
cent increase in radiolabeled incorporation pre and post-
treatment as compared to the control of undigested DNA.BMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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not only induces gene demethylation in roughly half the
evaluated gene/tumors, but we also observed re-expres-
sion in two-thirds of the informative cases. However, due
to the limited sample size of this study we could not
establish whether the effectiveness of this demethylating
agent is gene or patient-dependent.
At the present time there is limited information regarding
cancer treatment efficacy, demethylating and gene re-
expressing profiles of the various DNA demethylating
agents in the clinical setting. There are three clinical trial
reports evaluating 5-aza-2'-deoxycytidine. Two of these
were performed in patients with myelodysplasic syn-
drome and relapsed leukemia patients. Daskalakis et al.,
using the quantitative assay Ms-SNuPE found basal hyper-
methylation of p15 gene in 15/23 patients (65%) which
decreased in nine of 12 patients sequentially analyzed
after at least a course of low-dose decitabine. As expected,
reactivation of the p15 protein expression was found in
bone marrow biopsies of four out of eight patients ana-
lyzed in this study. Interestingly, response (3 CR) was
observed on all nine patients in whom p15 gene demeth-
ylation occurred [39]. More recently, a phase I study with
escalating doses of decitabine (5, 10, 15 or 20 mg/m2 IV
over 1 hour daily, 5 days a week for two consecutive
weeks) found responses in 11/18 patients (61%), how-
ever, no significant decline in p15 methylation after treat-
ment with decitabine regardless of the response was
observed. Moreover, in the three patients that showed
>50% demethylation, evaluated by the COBRA assay
there was no response. Authors speculated on the poor
sensitivity of this technique to explain their results [40].
Evaluation of these nucleoside analogs in solid tumors
has also shown inconsistent results. Aparicio et al.,
reported a phase I study using 5-aza-2'-deoxycytidine in
patients with advanced solid tumors using escalating
doses of 20, 30, 40 mg/m2 using a 72-hour continuous
infusion every 28 days. The quantitative Methyl-Light
reaction was used to evaluate changes in promoter meth-
ylation in 19 genes but no consistent evidence of gene
demethylation was documented despite grade 4 neutro-
penia was found in almost a third of the patients. This lat-
ter finding argues against its use as DNA demethylating
agent in solid tumors because despite such toxicity the
steady-state levels reached during the study (0.1–0.2 µM)
are below the levels needed in vitro to demethylate gene
promoters [41]. On the other hand, a number of genes
showed increased methylation which could be derived
from the cytotoxicity of this nucleoside analog. It is well-
known that most of the cytotoxic agents lead to an
increase in DNA methylation in vitro and in cancer
patients [42].
Among the non-nucleoside demethylating agents, MG98,
a DNMT1 antisense oligonucleotide, has been tested in a
phase I study to treat solid tumors. In contrast to the stud-
ies discussed above no attempt was done to evaluate gene
methylation in tumors although DNMT1 mRNA levels
were investigated in peripheral blood cells; no consistent
decrease was observed [25].
Our results demonstrate that hydralazine is quite promis-
ing in regards to its gene demethylating and tumor sup-
pressor gene reactivating activities without significant side
effects. It is noteworthy that a dose-effect level in the fre-
quency of demethylation was not observed. A pharmacok-
inetic correlation analysis would have been useful for the
interpretation of these findings, nonetheless, the pharma-
cokinetics of this drug is relatively well-known and some
assumptions can be made. After a single 1 mg/kg oral dose
and after the fifth 1 mg/kg dose given every 12 hours, the
peak concentrations achieved are in the range of 0.12–
1.31 µM and 0.10–1.39 µM respectively and AUC values
range between: 4.0–30.4 and 3.2–38.5 µM-minute,
respectively [43]. These concentrations were likely
achieved in our patients at the doses used which are close
to the concentrations needed to achieve gene demethyla-
tion and re-expression in vitro [26]. It is not clear why we
observed such variable gene demethylation rates
irrespective of the doses used, this may be the result of the
small number of patients studied as well as the additional
variability imposed by the acetylator phenotype which
may vary from 30 to 70% according to some studies per-
formed in Latin American Hispanic populations [44].
After years characterizing the role of DNA methylation in
cancer, it has become clear that both hypermethylation
and hypomethylation are by their own cancer causative or
at least cancer promoting, in animal models. This has led
to consider the use of demethylating agents for cancer
Table 6: Frecuency of promoter methylation of individual genes (%).
APC ER FHIT GSTp1 MGMT P16 RARB DAPK ANY
This study 94 25 88 88 81 19 62 100 70
Narayan (ref 35) 11 - 11 - 5 8.5 29 45 86
Virmani (ref 34) - - 32 21 26 42 26 - 74
Dong (ref 36) 32 - - - 8 30 - 51 79BMC Cancer 2005, 5:44 http://www.biomedcentral.com/1471-2407/5/44
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treatment a two-edge sword [45]. Such consideration is
debatable as the profound DNA demethylation levels
achieved in animal models can be hardly pharmacologi-
cally reproduced in patients. The present study demon-
strates that hydralazine at the doses used not only does
not demethylate genes which are "normally methylated"
such as H19 and clone 2.1 but also fails to produce global
DNA demethylation as evaluated by capillary electro-
phoresis which is a powerful and accurate method to
quantitate methylated and unmethylated cytosines [46],
and by cytosine extension assay which is also a sensitive
method to underscore abnormal methylation patterns
[31]. We can only speculate on the nature of these find-
ings. At the individual gene level, a plausible explanation
could be that certain "normally methylated" genes could
lie within a milieu prone to rapid re-methylation and/or
that certain genes have higher "availability" of the ele-
ments that compose the methylation machinery, there-
fore the demethylating agent would fail to produce
demethylation of these sequences at least at a detectable
levels by the current methods of analysis. This view is sup-
ported by the reporting that in mice 5-azacytidine does
not change the methylation status of H19 [47]. In regard
to global DNA methylation changes most likely is just a
matter of dose as we have in vitro evidence that hydrala-
zine produces global DNA hypomethylation in MCF-7
cells as evaluated by the same methods here used. Alterna-
tively, changes in global mC content induced by hydrala-
zine are not sufficient to be detected by the methods we
used.
Conclusion
In conclusion, hydralazine used at standard doses for the
treatment of cardiovascular conditions is an effective
demethylating and tumor suppressor gene transcriptional
reactivator causing no decrease in DNA mC content for
solid tumors. Our results are in agreement with those
reported by Chan et al., who found substantial degrees of
demethylation at all latent and lytic Epstein-Barr virus
promoters examined by methylation-specific PCR in
nasopharyngeal cancer patients treated with 5-azacytidine
[48]. A phase II clinical study using hydralazine in combi-
nation with standard cytotoxic chemotherapy is being
planned as proof of concept that the reactivation of tumor
suppressor genes silenced by DNA methylation increases
chemotherapy efficacy in solid tumors.
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